Zucker, Birgit <br/><br/>
Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease.  [electronic resource] 

 -  Naunyn-Schmiedeberg's archives of pharmacology  Aug 2004 
 - 131-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0028-1298 
<br/><br/><label>Standard No.: </label>10.1007/s00210-004-0959-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amines--therapeutic use<br/>Animals<br/>Anticonvulsants--therapeutic use<br/>Aza Compounds--blood<br/>Corpus Striatum--metabolism<br/>Cyclohexanecarboxylic Acids--therapeutic use<br/>Disease Models, Animal<br/>Female<br/>Gabapentin<br/>Hippocampus--metabolism<br/>Huntington Disease--drug therapy<br/>Injections, Subcutaneous<br/>Male<br/>Mice<br/>Mice, Transgenic<br/>Motor Activity--drug effects<br/>Neuroprotective Agents--therapeutic use<br/>Spiro Compounds--blood<br/>Survival Rate<br/>gamma-Aminobutyric Acid--therapeutic use